Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Drug Metabolism and Disposition: the Biological Fate of Chemicals|January 11, 2012
Effects of the CYP2B6*6 allele on catalytic properties and inhibition of CYP2B6 in vitro: implication for the mechanism of reduced efavirenz metabolism and other CYP2B6 substrates in vivoCong Xu, Evan T Ogburn, Yingying Guo, et al.Antimicrobial Agents and Chemotherapy|February 2, 2011
Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenzDoo-Yeoun Cho, Evan T Ogburn, David Jones, et al.Analytical Chemistry|May 24, 2011
Microfabricated electrochemical detector for high-performance liquid chromatographyEvan T Ogburn, Michael Dziewatkoski, Don Moles, et al.Drug Metabolism and Disposition: the Biological Fate of Chemicals|March 26, 2010
Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylationEvan T Ogburn, David R Jones, Andrea R Masters, et al.Xenobiotica; the Fate of Foreign Compounds in Biological Systems|May 23, 2012
Stereoselective and regiospecific hydroxylation of ketamine and norketamineZeruesenay Desta, Ruin Moaddel, Evan T Ogburn, et al.Springerplus|March 12, 2013
CYP2D6 genotypes, endoxifen levels, and disease recurrence in 224 Filipino and Vietnamese women receiving adjuvant tamoxifen for operable breast cancerRichard R Love, Zuerenesay Desta, David Flockhart, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 20, 2011
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter studyWilliam J Irvin, Christine M Walko, Karen E Weck, et al.Pageof 1